Human Medicine:

ADXBLADDER DIAGNOSTIC TEST FOR BLADDER CANCER

SYNLAB works closely with private clinics, hospitals, and occupational health / wellness providers to offer a wide range of pathology tests.

Through direct relationships with urologists, SYNLAB enables urologists to add ADXBLADDER, a non-invasive diagnostic test for bladder cancer, to their portfolio of urology tests.

WHAT IS THE ADXBLADDER TEST?

  • Non-invasive urine test – full test kit supplied.
  • Urinary biomarkers can act as a non-subjective method of detecting the presence of bladder cancer cells.
  • MCM5 is a novel biomarker of growth and in normal urothelium expression is restricted to the basal proliferative compartment.
  • In urothelial carcinomas, MCM5 is expressed in all layers resulting in the exfoliation of MCM5-expressing tumour cells into the urine.

WHICH PATIENTS IS THE ADXBLADDER TEST SUITABLE FOR?

The ADXBLADDER test can be used for both initial haematuria investigations as well as post bladder cancer treatment as recurrent tumours can occur.

  • Simple non-invasive urine test for haematuria investigations for patients presenting typical bladder cancer symptoms.
  • Regular post bladder cancer treatment test to monitor any recurrence.
  • Results indicate whether there is possibility of bladder cancer, which can then be followed up with a cystoscopy if required.

For further information on offering ADXBLADDER at your clinic, please contact [email protected].

Any patients interested in bladder cancer testing should contact their clinic / urologist.

Latest Human Medicine News
SYNLAB Announce Agreement with Arquer Diagnostics for Bladder Cancer Testing

13 July 2020 SYNLAB UK & Ireland and Arquer Diagnostics, a UK-based company committed to manufacturing and marketing innovative, non-invasive tests for diagnosing and monitoring…

Read More (about 'SYNLAB Announce Agreement with Arquer Diagnostics for Bladder Cancer Testing')
SYNLAB Laboratory Services Maintains ISO 15189:2012 UKAS Accreditation

7th April 2020 – SYNLAB Laboratory Services, part of Europe’s leading medical diagnostics provider SYNLAB Group, is pleased to announce that the company has successfully…

Read More (about 'SYNLAB Laboratory Services Maintains ISO 15189:2012 UKAS Accreditation')
Press Statement: SYNLAB UK & Ireland Confirmed as Preferred NHS Strategic Partner

21 January 2020 SYNLAB UK & Ireland has been confirmed as the preferred strategic partner to transform and deliver NHS pathology services in South East London. SYNLAB…

Read More (about 'Press Statement: SYNLAB UK & Ireland Confirmed as Preferred NHS Strategic Partner')